Instructions ACC (aminocaproic acid) solution 50 mg/ml container 2 ml No. 10
Composition
active ingredient: aminocaproic acid;
1 ml of solution contains 50 mg of aminocaproic acid;
Excipients: sodium chloride, water for injections.
Dosage form
Solution.
Main physicochemical properties: colorless transparent liquid.
Pharmacotherapeutic group
Antihemorrhagic agents. Fibrinolysis inhibitors. Amino acids. ATC code B02A A01.
Pharmacological properties
Pharmacodynamics
Aminocaproic acid has antiallergic, antiviral effects, enhances the detoxification function of the liver. It inhibits the proteolytic activity associated with the influenza virus. Aminocaproic acid has an inhibitory effect on the early stages of the interaction of the virus with sensitive cells, and also suppresses the proteolytic activity of hemagglutinin. As a result, a functionally active protein of the influenza virus, which ensures its infectious activity, is not created, and the amount of daughter infectious virus is reduced. Aminocaproic acid not only exhibits antiviral activity, but also improves some cellular and humoral indicators of specific and nonspecific protection of the body in respiratory viral infections.
Pharmacokinetics
Pharmacokinetics have not been studied with topical administration.
Indication
Treatment and prevention of influenza and acute respiratory viral infections in children and adults.
Contraindication
Hypersensitivity to the drug. With a tendency to thrombosis and thromboembolic diseases; coagulopathy due to diffuse intravascular coagulation; kidney disease with impaired function; thromboembolism, renal failure, hematuria; childbirth; pregnancy or breastfeeding; severe ischemic heart disease, cerebrovascular accident.
Interaction with other medicinal products and other types of interactions
The effect of the drug is weakened by anticoagulants and antiplatelet agents of direct and indirect action.
Concomitant use with estrogen-containing contraceptives and blood clotting factor IX increases the risk of thromboembolism.
Use with caution in patients taking retinoids (including tretinoin).
Application features
Use with caution in patients with heart disease. If there is a need to use the drug in patients with heart disease. If there is a need to use the drug in patients with heart disease, it is recommended to monitor the level of creatine phosphokinase in the blood plasma. Do not use the remaining drug.
Use during pregnancy or breastfeeding
The drug is contraindicated during pregnancy or breastfeeding.
If necessary, breastfeeding should be discontinued.
Ability to influence reaction speed when driving vehicles or other mechanisms
During the treatment period, you should refrain from driving vehicles and performing potentially dangerous activities due to possible adverse reactions from the central nervous system.
Method of administration and doses
For the prevention and treatment of influenza and acute respiratory viral infections, the drug should be used topically (0.5-1.0 ml in the nose 3-4 times a day) and orally.
When used topically, it is recommended to apply to the nasal passages every 3-4 hours.
For 5-10 minutes, use cotton swabs moistened with a 5% solution of aminocaproic acid, or instill (drip) 3-5 drops of the solution into each nasal passage at the specified times.
Aminocaproic acid can be used in combination with other antiviral drugs and interferon and its inducers, if necessary.
Intranasal instillations of aminocaproic acid (3-4 times a day) are advisable to be carried out during the influenza epidemic period for the purpose of prevention, which should be supplemented with enteral (as in treatment) use of the drug in foci of infection upon contact with the patient.
For oral use, it is recommended to use aminocaproic acid in 100 ml bottles.
The drug should be administered orally to children in doses:
– children under two years old – 1-2 g (20-40 ml of 5% solution per day) – 1-2 teaspoons
4 times a day (0.02-0.04 g/kg – single dose), can be added to food or drinks;
– children aged 2 to 6 years – 2-4 g (40-80 ml of 5% solution per day) –
1-2 tablespoons 4 times a day;
– children over 7 years of age and adults – 4-5 g (80-100 ml of 5% solution per day), dividing the daily dose into 4 doses.
For more accurate dosing of the solution, it is advisable to use a medical syringe without a needle with a volume of 10 or 20 ml.
The duration of oral administration of aminocaproic acid for influenza and acute respiratory viral infections is 3-7 days.
The duration of treatment depends on the severity of the disease and is determined by the doctor individually. The doctor may also adjust the dose and prescribe a repeated course of treatment.
Children
There is no data on restrictions on the use of the drug in children.
Overdose
Sudden decrease in fibrinolytic activity of the blood. Severe side effects: dizziness, nausea, diarrhea, skin rash, orthostatic hypotension, convulsions, headache, nasal congestion, acute renal failure, rhabdomyolysis, myoglobinuria. Increased adverse reactions, thromboembolism. With prolonged use (more than 6 days) of high doses (for adults - more than 24 g per day) - hemorrhages.
Treatment: In case of overdose, discontinue administration of the drug and provide appropriate symptomatic therapy.
Adverse reactions
Cardiovascular system: orthostatic hypotension, bradycardia, arrhythmias.
On the part of the digestive system: nausea, vomiting, diarrhea.
From the side of the blood coagulation system: blood clotting disorders, with prolonged use (more than 6 days) of high doses (for adults - more than 24 g per day) - hemorrhages.
From the side of the central nervous system: headache, dizziness, tinnitus, convulsions.
On the part of the immune system: hypersensitivity reactions, including allergic reactions, rash, nasal congestion, catarrhal phenomena of the upper respiratory tract.
Expiration date
3 years.
Storage conditions
Store at a temperature not exceeding 25 °C in the original packaging. Keep out of the reach of children.
Packaging
2 ml or 5 ml per container; 10 containers per pack.
Vacation category
Without a prescription.
Producer
LLC "Yuria-Pharm".
Location of the manufacturer and its business address
Ukraine, 18030, Cherkasy, Verbovetskogo St., 108.
Phone/fax: (044) 281-01-01.
